Clinical trial
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and…
NCT00304460 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00304460 |
|---|---|
| Title | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer |
| Official title | Studies on the Mechanism of Action of High-Dose IL-2 in Metastatic Melanoma and Renal Cell Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma, Renal Cell Cancer |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Enrollment | 138 |
| Start date | Mar 13, 2006 |
| Primary completion | Feb 27, 2014 |
| Completion | Feb 27, 2014 |
| First posted | Mar 17, 2006 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: